Suppression of Tumor Growth in Vivo by Local and Systemic 90K Level Increase
B Jallal, J Powell, J Zachwieja, C Brakebusch… - Cancer research, 1995 - AACR
B Jallal, J Powell, J Zachwieja, C Brakebusch, L Germain, J Jacobs, S Iacobelli, A Ullrich
Cancer research, 1995•AACRExpression levels of the immunostimulatory 90K antigen in mammary carcinoma,
glioblastoma, and other tumor-derived cell lines inversely correlate with their tumorigenicity
in athymic mice. Engineered enhancement of 90K expression results in significant (> 80%)
tumor growth inhibition, not by direct action on the tumor cell, but by stimulation of the
residual cell-mediated immune defense of the nude mouse. Enhanced 90K level effects are
both localized and systemic and involve induction of ICAM-1 and VCAM-1 in the tumor …
glioblastoma, and other tumor-derived cell lines inversely correlate with their tumorigenicity
in athymic mice. Engineered enhancement of 90K expression results in significant (> 80%)
tumor growth inhibition, not by direct action on the tumor cell, but by stimulation of the
residual cell-mediated immune defense of the nude mouse. Enhanced 90K level effects are
both localized and systemic and involve induction of ICAM-1 and VCAM-1 in the tumor …
Abstract
Expression levels of the immunostimulatory 90K antigen in mammary carcinoma, glioblastoma, and other tumor-derived cell lines inversely correlate with their tumorigenicity in athymic mice. Engineered enhancement of 90K expression results in significant (>80%) tumor growth inhibition, not by direct action on the tumor cell, but by stimulation of the residual cell-mediated immune defense of the nude mouse. Enhanced 90K level effects are both localized and systemic and involve induction of ICAM-1 and VCAM-1 in the tumor endothelium. The findings presented suggest a role for 90K as a molecular alarm signal for the body's cellular defense against pathogens, which in a subset of tumors is suppressed to allow cancer progression.
AACR